Clinical trials: LDL-C
MASH
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects.
- Trial name
- NCT06485245
- Testing
- CS060304
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Hypercholesteremia
Phytosterol Supplementation and Cardiovascular Risk
This study examined the effects of 2.6 g/d of phytosterol ingestion on LDL cholesterol metabolism. It is expected that this dose will significantly reduce LDL cholesterol after 12 weeks of supplementation.
- Trial name
- NCT00153738
- Testing
- phytosterol
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Cooper Institute
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol.
- Trial name
- NCT05905068
- Testing
- RN0191 INJECTION
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
Cardiovascular Diseases
Happy Gut Study - Fermented Vegetables and Cardiovascular Biomarkers
The purpose of this project is to determine whether regular consumption of fermented vegetables can decrease inflammation and change the types of bacteria that are normally present in the large intestine.
- Trial name
- NCT04887662
- Testing
- Fermented vegetable
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of North Florida
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Body Mass Index Quantitative Trait Locus 8 Disorder, Tangier Disease
High Protein Weight Loss Diet, High Sensitivity C-Reactive Protein and Cardiovascular Risks Among Obese Women
The investigators aimed to determine the effects of HP diet on CVD risk factors and hs-CRP among overweight and obese women.
- Trial name
- NCT01763528
- Testing
- nutrition intervention
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Combined Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin
1. Target disease : Patients with combined dyslipidemia with adequately controlled LDL-C but inadequately controlled triglyceride level by atorvastatin monotherapy 2.
- Trial name
- NCT02166593
- Testing
- Pravastatin40mg/Fenofibrate160mg, Atorvastatin Sodium 10mg
- Where
- South Korea
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density…
- Trial name
- NCT05384262
- Testing
- AZD0780, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, NAFLD
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.
- Conditions
- Healthy, NAFLD, Hyperlipidemia
- Trial name
- NCT04692025
- Testing
- ASC41 tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10582 following single and multiple dose administration to healthy subjects and subjects with Mildly Elevated LDL-C.
- Trial name
- NCT07777003
- Testing
- HS-10582
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Volunteer
Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of orally administered lomitapide in healthy male Japanese and Caucasian subjects with elevated LDL-C.
- Trial name
- NCT01760187
- Testing
- lomitapide
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hypercholesterolemia
Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)
To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
- Trial name
- NCT00457275
- Testing
- MK0653, ezetimibe / Duration of Treatment: 4 Weeks
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Healthy Volunteers
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body…
- Trial name
- NCT01618916
- Testing
- LY3015014
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Hypercholesterolemia, Cardiovascular Disease
A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy
This study is being conducted to test the hypothesis that daily consumption of a baked food product containing whole soy for 6 weeks will significantly reduce plasma Low Density Lipoprotein Cholesterol (LDL-C) in individuals with…
- Conditions
- Hypercholesterolemia, Cardiovascular Disease, CRP
- Trial name
- SOY-LDL (NCT01547585)
- Testing
- Standardized soy containing muffin
- Where
- 3 sites in Canada
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Guelph Food Research Centre
Cholesterol Variability, Trained Immunity
LDL-c Level Variability and Trained Immunity
Statin treatment significantly reduces the incidence of cardiovascular events. However, cholesterol variability is associated with the risk of adverse events such as mortality, myocardial infarction, and stroke.
- Trial name
- NCT05790499
- Testing
- Atorvastatin
- Where
- China
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hypercholesterolemia, Familial
Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)
This is a 105-week clinical study in patients with heterozygous familial hypercholesterolemia on intensive Low Density Lipoprotein-cholesterol (LDL-C) lowering therapy intended to assess the affects of MK0524A on carotid intima…
- Trial name
- ACHIEVE (NCT00384293)
- Testing
- Comparator: niacin (+) laropiprant (MK0524A)
- Volunteers
- 937 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT01426412
- Testing
- LY3015014 IV, LY3015014 SC
- Where
- 3 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Hypercholesterolemia
A Study of LY3015014 in Healthy Participants With High Cholesterol
This is a study in healthy participants with high levels of "bad" cholesterol who are already taking a popular type of cholesterol-lowering medication called statins.
- Trial name
- NCT01671085
- Testing
- LY3015014
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company